Sign In
Free Newsletter
Trump 100% pharma tariffs raise concerns for New Jersey life sciences (updated)
The president's levies on imported drugs and ingredients raise concerns for New Jersey’s life sciences sector, with risks to costs and innovation.
Costco, IVI RMA launch discounted fertility care program
Costco, IVI RMA North America and Sesame launch a fertility care program, offering IVF coordination and medication discounts for members.
NJ sues Novartis over alleged generic drug price fixing
New Jersey joins a multistate lawsuit accusing Novartis and Sandoz of price fixing 31 generic drugs, raising costs for consumers, Medicare and Medicaid.
NJ pharma drugs among 15 targeted in Medicare price talks (updated)
CMS targets 15 high-spend drugs for Medicare price negotiations, including therapies from New Jersey-based Novartis, Johnson & Johnson and Bristol Myers Squibb.
Novo Nordisk’s Wegovy weight loss pill hits US market
The pharma launched a once-daily alternative to its injections, available nationwide after FDA approval at 70,000 pharmacies with starting doses priced at $149 per month.
FDA approves Wegovy weight loss pill from Novo Nordisk
The first oral GLP-1 obesity drug will launch in the U.S. at a $149 starting price in 2026.
NJ pharma firms join Trump drug pricing deals
Four Garden State companies are among the latest to strike agreements with the White House to lower prescription costs under the president's policy.
US, UK finalize pharma pricing deal to boost innovation
The agreement raises United Kingdom payments for medicines, easing cost pressures domestically as well as strengthening United States life sciences investment.
Novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare
The deals with the Trump administration will lower prices for weight loss and diabetes medications to make them more affordable for patients.
Appeals court rejects NJ pharma challenges to Medicare drug pricing (updated)
New Jersey giants, including J&J, BMS and Novartis, have all lost challenges to the Inflation Reduction Act program, setting up the U.S. Supreme Court as the last lever remaining for potential relief.
Trump drug pricing order draws NJ pharma industry backlash
Local industry leaders say the attempt to lower costs could harm innovation, threaten jobs and import failed foreign pricing models to U.S. markets.
Wegovy, Ozempic targeted for Medicare price negotiations (updated)
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.
